Sangamo BioSciences | SGMO - Przychody Ze Sprzedaży





Obroty Zmiana Data
Alaunos Therapeutics USD 2K 2K 2025-03
Alnylam Pharmaceuticals USD 1.17B 70M 2026-03
Alterity Therapeutics Limited AUD 596.04K 584.66K 2025-12
Amgen USD 8.62B 1.28B 2026-03
Bayer EUR 13.41B 1.97B 2026-03
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Biogen USD 2.25B 30M 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Cipla INR 71.19B 5.78B 2026-06
Clal Biotechnology ILS 3.41M 2M 2022-12
Compugen USD 6.35M 60.98M 2026-03
CSL USD 8.33B 4.79B 2025-12
Gilead Sciences USD 7B 930M 2026-03
GlaxoSmithKline GBP 7.63B 991M 2026-03
Grifols EUR 2B 306.7M 2026-03
Ionis Pharmaceuticals USD 246M 43M 2026-03
J&J USD 25.31B 1.21B 2026-06
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
Merck USD 16.29B 110M 2026-03
Novartis USD 14.41B 1.3B 2026-06
Pfizer USD 14.5B 3.08B 2026-03
Roche Holding CHF 30.36B 14.71B 2026-06
Sangamo BioSciences USD 356K 125K 2024-06
Sanofi EUR 11.24B 60M 2026-03
Sarepta Therapeutics USD 730.8M 287.9M 2026-03
Tectonic Therapeutic USD 0 0 2024-12
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Vertex Pharmaceuticals USD 2.99B 200M 2026-03